Publicação: Sodium nitrite prevents both reductions in circulating nitric oxide and hypertension in 7-day lead-treated rats
dc.contributor.author | Gonçalves-Rizzi, Victor Hugo [UNESP] | |
dc.contributor.author | Nascimento, Regina Aparecida [UNESP] | |
dc.contributor.author | Possomato-Vieira, Jose Sergio [UNESP] | |
dc.contributor.author | Dias-Junior, Carlos A. [UNESP] | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2015-12-07T15:32:44Z | |
dc.date.available | 2015-12-07T15:32:44Z | |
dc.date.issued | 2015 | |
dc.description.abstract | Hypotensive effects of oral sodium nitrite have been reported as alternative sources of nitric oxide (NO) formation in animals and human beings. Reductions in NO bioavailability were observed in lead-induced hypertension. However, no previous study has examined whether a single daily dose of sodium nitrite prevents the reductions in the NO bioavailability in lead-induced hypertension. Then, we expanded previous reports and evaluated the effects of sodium nitrite in 7-day lead-treated rats. Wistar rats were divided into four experimental groups: Pb+sodium nitrite group received intraperitoneally (i.p.) 1st dose 8 µg/100 g of lead acetate and a subsequent dose of 0.1 µg/100 g, and daily treatment with sodium nitrite (45 mg/kg/day) or water (Pb group) by gavage for 7 days; Sodium nitrite group received i.p. 1st dose 8 µg/100 g of sodium acetate and a subsequent dose of 0.1 µg/100 g, and daily treatment with sodium nitrite (45 mg/kg/day) or water (saline group) by gavage for 7 days. Similar and higher whole-blood lead levels (11.5 ± 1.2 and 13.2 ± 0.7 µg/dL) were found in lead-exposed rats treated with either water or sodium nitrite (Pb or Pb+sodium nitrite, respectively; both p < 0.05 versus control groups). We found lower NO markers such as plasma nitrite and nitrite + nitrate (NOx) levels (both p < 0.05 versus controls) in lead-exposed rats compared with normotensive (sodium acetate)-treated controls (Pb group versus saline group; p < 0.05). Lead induced increases in systolic blood pressure (from 130 ± 2 to 164 ± 6 mmHg in Pb group; p < 0.05); however, both lead-induced decreases in NO markers and hypertension (Pb+sodium nitrite group versus Pb group; both p < 0.05) were prevented by a single daily dose of sodium nitrite. In conclusion, these findings are consistent with the idea that impaired NO bioavailability contributes to the maintenance of elevated blood pressure in lead-induced hypertension. Additionally, our results show that sodium nitrite exerts antihypertensive effects in lead-induced hypertension and provide evidence that sodium nitrite prevents the impairment of NO, thus, reaffirming the relevance of nitrite as alternative source of recycling back to NO. | en |
dc.description.affiliation | Departamento de Farmacologia, Instituto de Biociências de Botucatu (IBB), Universidade Estadual Paulista (UNESP), Botucatu, SP, Brasil | |
dc.description.affiliationUnesp | Departamento de Farmacologia, Instituto de Biociências de Botucatu (IBB), Universidade Estadual Paulista (UNESP), Botucatu, SP, Brasil | |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
dc.identifier | http://dx.doi.org/10.1111/bcpt.12480 | |
dc.identifier.citation | Basic & Clinical Pharmacology & Toxicology, 2015. | |
dc.identifier.doi | 10.1111/bcpt.12480 | |
dc.identifier.issn | 1742-7843 | |
dc.identifier.pubmed | 26333850 | |
dc.identifier.uri | http://hdl.handle.net/11449/131219 | |
dc.language.iso | eng | |
dc.publisher | Nordic Association for the Publication of BCPT | |
dc.relation.ispartof | Basic & Clinical Pharmacology & Toxicology | |
dc.rights.accessRights | Acesso restrito | |
dc.source | PubMed | |
dc.title | Sodium nitrite prevents both reductions in circulating nitric oxide and hypertension in 7-day lead-treated rats | en |
dc.type | Artigo | |
dcterms.rightsHolder | Nordic Association for the Publication of BCPT | |
dspace.entity.type | Publication | |
unesp.author.lattes | 6296664642422599[4] | |
unesp.author.orcid | 0000-0002-0348-6144[4] | |
unesp.campus | Universidade Estadual Paulista (UNESP), Instituto de Biociências, Botucatu | pt |
unesp.department | Farmacologia - IBB | pt |